JP2024519629A5 - - Google Patents
Info
- Publication number
- JP2024519629A5 JP2024519629A5 JP2023513604A JP2023513604A JP2024519629A5 JP 2024519629 A5 JP2024519629 A5 JP 2024519629A5 JP 2023513604 A JP2023513604 A JP 2023513604A JP 2023513604 A JP2023513604 A JP 2023513604A JP 2024519629 A5 JP2024519629 A5 JP 2024519629A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weeks
- dose
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189541P | 2021-05-17 | 2021-05-17 | |
| US63/189,541 | 2021-05-17 | ||
| US202163235398P | 2021-08-20 | 2021-08-20 | |
| US63/235,398 | 2021-08-20 | ||
| US202263297420P | 2022-01-07 | 2022-01-07 | |
| US63/297,420 | 2022-01-07 | ||
| US202263306315P | 2022-02-03 | 2022-02-03 | |
| US63/306,315 | 2022-02-03 | ||
| PCT/US2022/029462 WO2022245739A1 (en) | 2021-05-17 | 2022-05-16 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519629A JP2024519629A (ja) | 2024-05-21 |
| JP2024519629A5 true JP2024519629A5 (enExample) | 2025-05-23 |
Family
ID=81975181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513604A Pending JP2024519629A (ja) | 2021-05-17 | 2022-05-16 | 血管新生性眼疾患の治療のための長期の高用量ｖｅｇｆアンタゴニストレジメン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230302085A1 (enExample) |
| EP (2) | EP4647125A3 (enExample) |
| JP (1) | JP2024519629A (enExample) |
| KR (1) | KR20240008821A (enExample) |
| AU (2) | AU2022275786C1 (enExample) |
| BR (1) | BR112023023002A2 (enExample) |
| CA (1) | CA3190663A1 (enExample) |
| CL (3) | CL2023003396A1 (enExample) |
| DK (1) | DK4185318T3 (enExample) |
| ES (1) | ES3041647T3 (enExample) |
| FI (1) | FI4185318T3 (enExample) |
| HR (1) | HRP20251282T8 (enExample) |
| IL (1) | IL308505A (enExample) |
| JO (1) | JOP20230283A1 (enExample) |
| LT (1) | LT4185318T (enExample) |
| MX (1) | MX2023013554A (enExample) |
| PE (1) | PE20240922A1 (enExample) |
| PL (1) | PL4185318T3 (enExample) |
| PT (1) | PT4185318T (enExample) |
| RS (1) | RS67369B1 (enExample) |
| SI (1) | SI4185318T1 (enExample) |
| TW (1) | TW202313095A (enExample) |
| WO (1) | WO2022245739A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| TW202400214A (zh) * | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
| US20230295266A1 (en) * | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) * | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
| KR20260096819A (ko) * | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| CA2866232A1 (en) | 2012-05-25 | 2013-11-28 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015173260A1 (en) | 2014-05-12 | 2015-11-19 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| IL318292A (en) | 2017-12-13 | 2025-03-01 | Regeneron Pharma | Devices and methods for administering precise doses |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020345174A1 (en) * | 2019-09-12 | 2022-03-31 | Lupin Limited | Modified dosing of VEGF inhibitors for ophthalmic use |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021129658A1 (zh) | 2019-12-24 | 2021-07-01 | 信达生物制药(苏州)有限公司 | 融合蛋白在治疗年龄相关性黄斑变性中的应用 |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US20230295266A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| TW202400214A (zh) | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
-
2022
- 2022-05-16 FI FIEP22728724.0T patent/FI4185318T3/fi active
- 2022-05-16 IL IL308505A patent/IL308505A/en unknown
- 2022-05-16 TW TW111118217A patent/TW202313095A/zh unknown
- 2022-05-16 MX MX2023013554A patent/MX2023013554A/es unknown
- 2022-05-16 AU AU2022275786A patent/AU2022275786C1/en active Active
- 2022-05-16 US US18/021,802 patent/US20230302085A1/en active Pending
- 2022-05-16 LT LTEPPCT/US2022/029462T patent/LT4185318T/lt unknown
- 2022-05-16 EP EP25189523.1A patent/EP4647125A3/en active Pending
- 2022-05-16 ES ES22728724T patent/ES3041647T3/es active Active
- 2022-05-16 BR BR112023023002A patent/BR112023023002A2/pt unknown
- 2022-05-16 WO PCT/US2022/029462 patent/WO2022245739A1/en not_active Ceased
- 2022-05-16 EP EP22728724.0A patent/EP4185318B1/en active Active
- 2022-05-16 PE PE2023003023A patent/PE20240922A1/es unknown
- 2022-05-16 PL PL22728724.0T patent/PL4185318T3/pl unknown
- 2022-05-16 CA CA3190663A patent/CA3190663A1/en active Pending
- 2022-05-16 HR HRP20251282TT patent/HRP20251282T8/hr unknown
- 2022-05-16 KR KR1020237013896A patent/KR20240008821A/ko active Pending
- 2022-05-16 RS RS20251029A patent/RS67369B1/sr unknown
- 2022-05-16 JP JP2023513604A patent/JP2024519629A/ja active Pending
- 2022-05-16 DK DK22728724.0T patent/DK4185318T3/da active
- 2022-05-16 PT PT227287240T patent/PT4185318T/pt unknown
- 2022-05-16 SI SI202230175T patent/SI4185318T1/sl unknown
-
2023
- 2023-11-06 JO JOJO/P/2023/0283A patent/JOP20230283A1/ar unknown
- 2023-11-14 CL CL2023003396A patent/CL2023003396A1/es unknown
-
2024
- 2024-10-02 CL CL2024002972A patent/CL2024002972A1/es unknown
-
2025
- 2025-04-29 CL CL2025001269A patent/CL2025001269A1/es unknown
- 2025-09-04 AU AU2025226774A patent/AU2025226774A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Samanta et al. | Emerging therapies in neovascular age-related macular degeneration in 2020 | |
| US11738064B2 (en) | Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
| JP2023071798A5 (enExample) | ||
| FI4185318T3 (fi) | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon | |
| JP2023099094A5 (enExample) | ||
| FI4364724T3 (fi) | Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita | |
| JP2025084976A5 (enExample) | ||
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP2017061467A5 (enExample) | ||
| CN103533950A (zh) | Vegf拮抗剂在治疗血管生成眼病中的用途 | |
| WO2014203183A1 (en) | Use of a vegf antagonist in treating macular edema | |
| US11944663B2 (en) | Method for treating angiogenic eye disorders using VEGF antagonists | |
| JP7828274B2 (ja) | 眼疾患を治療するための方法 | |
| US20130004486A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| Sawada et al. | Retinal vein occlusion | |
| Khandelwal et al. | Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview | |
| WO2025061000A1 (zh) | 一种用于治疗受试者中与血管新生相关的眼病的方法 | |
| El Hatew | Recent Trends of Antiangiogenic Drugs in Ophthalmology | |
| Chan | Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Baltimore, Maryland, USA-May 7-11, 2017 | |
| CN120965891A (zh) | 同时靶向bmp-2与vegf-a的双特异性抗体融合蛋白及其在制备糖尿病视网膜病变治疗药物中的应用 | |
| Surgeon | Use of anti-VEGFs in Resource Poor Settings | |
| Ng | Injection |